Revista Española de Enfermedades Digestivas The spanish journal of gastroenterology

Title: Desmoid fibromatosis of the esophagogastric junction

Authors: Raquel Díaz Ruiz , Virginia Flores Fernández, Jose Antonio Pajares Díaz

DOI: 10.17235/reed.2018.5630/2018 Link: <u>PubMed (Epub ahead of print)</u>

Please cite this article as: Díaz Ruiz Raquel, Flores Fernández Virginia, Pajares Díaz Jose Antonio. Desmoid fibromatosis of the esophagogastric junction. Rev Esp Enferm Dig 2018. doi: 10.17235/reed.2018.5630/2018.



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



CE 5630

Desmoid fibromatosis of the esophagogastric junction

Raquel Díaz-Ruiz, Virginia Flores-Fernández y José Antonio Pajares-Díaz

Digestive Diseases Service. Hospital General Universitario Gregorio Marañón. Madrid

Correspondence: Raquel Díaz Ruiz e-mail: diaz.ruiz.r@gmail.com

Key words: Desmoid fibromatosis. B-catenin. FAP.

Dear Editor,

Desmoid fibromatosis is a mesenchymal clonal proliferation which lacks metastatic potential. Nevertheless, it has an infiltrative growth and thus implies a high morbidity (1). Although the etiology remains unclear, mutations in the B-catenin or APC genes are involved. Some risk factors include pregnancy, hormonal exposure or surgery. Desmoid fibromatosis can be sporadic (80%) or FAP-associated (2). In sporadic cases, it is caused by mutations in the B-catenin (CTNNB1) gene. Whether it is FAP-associated or not should be determined, as the treatment for each condition is different. A radiologic test is essential for diagnosis, although a biopsy is necessary for confirmation. With regard to treatment, there is a wide range of different alternatives such as observation only, medical treatment or even surgery (3). However, a recurrence rate that ranges from 30% to 40% has been reported in the major published series (4) and thus, conservative treatment is more common nowadays.

Case report

We present the case of an 82-year-old male with constitutional syndrome. A computed tomography was performed, which identified a 69 x 52 mm mass in the esophagogastric union (Fig. 1). A computed tomography guided biopsy was performed and the histological analysis identified a fusocellular tumor compatible with desmoid fibromatosis. Treatment was started with indomethacin. However, a control computed

Revista Española de Enfermedades Digestivas

tomography three months later showed that the mass had grown. Thus, indomethacin treatment was stopped and tamoxifen treatment was started. The patient has had an excellent performance status since symptom presentation.

Conclusion

In conclusion, desmoid tumors are rare and most are sporadic. However, they may also be associated with familial adenomatous polyposis syndrome. It must be emphasized that our patient did not have any risk factors and the anatomical location in the esophagogastric union is not a common location. Desmoid fibromatosis represents a clinical challenge for diagnosis and treatment and thus, management should be individualized.

Bibliography

1. Kasper B, Strobel P, Hohenberger P, et al. Desmoid tumors: clinical features and treatment options for advanced disease. Oncologist 2011;16:682-93. DOI: 10.1634/theoncologist.2010-0281

2. Garzón Benavides M, Pizarro Moreno A, García Lozano R, et al. Registro Andaluz de la Poliposis Adenomatosa Familiar. Análisis de los pacientes incluidos. Rev Esp Enferm Dig 2010;102:653-7.

3. Escobar C, Munker R, Thomas JO, et al. Update on desmoid tumors. Ann Oncol 2012;23:562-9. DOI: 10.1093/annonc/mdr386

4. Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy or combined surgery and radiation therapy. J Clin Oncol 1999;17:158-67. DOI: 10.1200/JCO.1999.17.1.158



Fig. 1. ACT scan showing a 69 x 52 mm mass in the esophagogastric union (red circle).